PATHFINDER 2: A Multi-Cancer Early Detection Study
Public ClinicalTrials.gov record NCT05155605. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a prospective, multi-center interventional study of the GRAIL multi-cancer early detection (MCED) test with return of test results for participants enrolled through healthcare systems in North America. The purpose of this study is to evaluate the safety and performance of the GRAIL MCED test in a population of individuals who are eligible for guideline-recommended cancer screening. In cases with a "cancer signal detected" test result, participants will undergo diagnostic procedures based on the test returned cancer signal origin(s) to determine if they have cancer. The number and types of diagnostic procedures required to achieve diagnostic resolution will be assessed. Participant-reported outcomes will be collected at several time points to assess participants' perceptions about the multi-cancer early detection test. The study will enroll approximately 35,000 and no more than 38,500 participants as defined by eligibility criteria over an anticipated enrollment period of approximately 36 months at up to 40 clinical institutions within North America. Participants will be actively followed for approximately 3 years from the date of their enrollment.
Study identification
- NCT ID
- NCT05155605
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Not applicable
- Enrollment
- 35,883 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 50 Years and older
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 8, 2021 (Actual)
- Primary completion
- Feb 11, 2026 (Actual)
- Completion
- Apr 30, 2028 (Estimated)
- Last update posted
- May 14, 2026
2021 – 2028
United States locations
- U.S. sites
- 55
- U.S. states
- 20
- U.S. cities
- 48
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Sutter Health | Auburn | California | 95602 | — |
| Sutter Health | Davis | California | 95616 | — |
| Sutter Health | Elk Grove | California | 95758 | — |
| Sutter Health | Fairfield | California | 94534 | — |
| HOAG Irvine | Irvine | California | 92663 | — |
| HOAG Vivante Newport Mesa | Irvine | California | 92663 | — |
| Long Beach Memorial Medical Center | Long Beach | California | 90806 | — |
| Sutter Health | Modesto | California | 95355 | — |
| HOAG Newport Beach | Newport Beach | California | 92663 | — |
| Palo Alto Medical Foundation | Palo Alto | California | 94301 | — |
| Sutter Health | Sacramento | California | 95816 | — |
| PAMF - Santa Cruz | Santa Cruz | California | 95062 | — |
| PAMF - Sunnyvale | Sunnyvale | California | 94086 | — |
| Sarah Cannon Research Institute - Englewood Primary Care | Englewood | Colorado | 80113 | — |
| Medstar Washington Hospital Center | Northwest | District of Columbia | 20010 | — |
| Woodlands Medical Specialists | Pensacola | Florida | 32503 | — |
| Morehouse School of Medicine | Atlanta | Georgia | 30310 | — |
| University of Illinois at Chicago | Chicago | Illinois | 60608 | — |
| Ochsner Grove | Baton Rouge | Louisiana | 70836 | — |
| Ochsner Lafayette General | Lafayette | Louisiana | 70503 | — |
| Ochsner Health | New Orleans | Louisiana | 70127 | — |
| Maryland Oncology Hematology | Annapolis | Maryland | 21401 | — |
| Henry Ford Macomb | Clinton | Michigan | 48038 | — |
| Henry Ford Medical Center Ford Road | Dearborn | Michigan | 48126 | — |
| Henry Ford Health System | Detroit | Michigan | 48202 | — |
| Henry Ford Medical Center Harbortown | Detroit | Michigan | 48207 | — |
| Henry Ford Medical Center Detroit North West | Detroit | Michigan | 48235 | — |
| Henry Ford Medical Center Sterling Heights | Sterling Heights | Michigan | 48310 | — |
| Mayo Clinic - Cancer Center | Rochester | Minnesota | 55905 | — |
| Weill Cornell Medicine | New York | New York | 10065 | — |
| Flushing Hospital Medical Center | Queens | New York | 11355 | — |
| Jamaica Hospital Medical Center | Queens | New York | 11418 | — |
| Sarah Cannon Asheville Family Medicine | Asheville | North Carolina | 28801 | — |
| Duke University Health System | Durham | North Carolina | 27705 | — |
| Cleveland Clinic | Cleveland | Ohio | 44195 | — |
| University of Oklahoma | Oklahoma City | Oklahoma | 73104 | — |
| St. Charles Health System | Bend | Oregon | 97701 | — |
| Oregon Health & Science University Bay Area Hospital | Coos Bay | Oregon | 97420 | — |
| Oregon Health & Science University Knight Cancer Institute | Portland | Oregon | 97201 | — |
| SALEM Health | Salem | Oregon | 97301 | — |
| University of Pittsburgh Medical Center | Pittsburgh | Pennsylvania | 15213 | — |
| Sarah Cannon Research Institute - The Frist Clinic | Nashville | Tennessee | 37203 | — |
| Sarah Cannon, Centennial Internal Medicine Continuity Clinic | Nashville | Tennessee | 37203 | — |
| Texas Oncology - West Texas | Amarillo | Texas | 79106 | — |
| Sarah Cannon, Austin Diagnostic Clinic | Austin | Texas | 78758 | — |
| Kelsey-Seybold Clinic Cypress Woods | Houston | Texas | 77014 | — |
| Kelsey-Seybold Clinic Holcombe | Houston | Texas | 77025 | — |
| Texas Oncology - Plano East | Plano | Texas | 75075 | — |
| Texas Oncology - Plano West | Plano | Texas | 75093 | — |
| University Texas Health San Antonio - Mays Cancer Center | San Antonio | Texas | 78229 | — |
| Texas Oncology - Tyler | Tyler | Texas | 75702 | — |
| Inova | Fairfax | Virginia | 22031 | — |
| Eastern Virginia Medical School | Norfolk | Virginia | 23510 | — |
| Virginia Commonwealth University | Richmond | Virginia | 23219 | — |
| Northwest Cancer Specialists | Vancouver | Washington | 98684 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05155605, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 14, 2026 · Synced Oct 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05155605 live on ClinicalTrials.gov.